Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 1
1994 1
1996 1
1999 1
2003 2
2004 2
2005 3
2006 1
2008 2
2009 1
2010 2
2011 2
2012 1
2013 5
2014 4
2015 4
2016 5
2017 3
2018 2
2019 3
2020 2
2021 3
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
The pharmacokinetics of meropenem in volunteers.
Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ. Bax RP, et al. J Antimicrob Chemother. 1989 Sep;24 Suppl A:311-20. doi: 10.1093/jac/24.suppl_a.311. J Antimicrob Chemother. 1989. PMID: 2808215 Clinical Trial.
The plasma concentrations of meropenem were linearly related to dose. The half-life of meropenem was approximately 1 h and the urinary recovery of unchanged drug was 79%. In the presence of probenecid the plasma half-life of meropenem was increased by 33% but …
The plasma concentrations of meropenem were linearly related to dose. The half-life of meropenem was approximately 1 h and the …
Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
Kays MB, Fleming MR, Cheatham SC, Chung EK, Juenke JM. Kays MB, et al. Ann Pharmacother. 2014 Feb;48(2):178-86. doi: 10.1177/1060028013512474. Epub 2013 Nov 14. Ann Pharmacother. 2014. PMID: 24259653 Clinical Trial.
BACKGROUND: Antimicrobial pharmacokinetic and pharmacodynamic data are limited in obesity. OBJECTIVE: To evaluate the steady-state pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients hospitalized on a general ward. METHODS: Pati …
BACKGROUND: Antimicrobial pharmacokinetic and pharmacodynamic data are limited in obesity. OBJECTIVE: To evaluate the steady-state …
Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
Jamal JA, Mat-Nor MB, Mohamad-Nor FS, Udy AA, Wallis SC, Lipman J, Roberts JA. Jamal JA, et al. Int J Antimicrob Agents. 2015 Jan;45(1):41-5. doi: 10.1016/j.ijantimicag.2014.09.009. Epub 2014 Oct 18. Int J Antimicrob Agents. 2015. PMID: 25455853 Clinical Trial.
The objective of this study was to describe the pharmacokinetics of meropenem, administered by continuous infusion (CI) or intermittent bolus (IB), in critically ill patients receiving continuous venovenous haemofiltration (CVVH) and to evaluate the frequency of …
The objective of this study was to describe the pharmacokinetics of meropenem, administered by continuous infusion (CI) or int …
Pharmacokinetics of meropenem in patients with intra-abdominal infections.
Bedikian A, Okamoto MP, Nakahiro RK, Farino J, Heseltine PN, Appleman MD, Yellin AE, Berne TV, Gill MA. Bedikian A, et al. Antimicrob Agents Chemother. 1994 Jan;38(1):151-4. doi: 10.1128/AAC.38.1.151. Antimicrob Agents Chemother. 1994. PMID: 8141572 Free PMC article. Clinical Trial.
Noncompartmental and compartmental analyses of meropenem disposition in patients receiving 1-g intravenous intermittent infusions every 8 h were performed. Twelve patients (one woman and 11 men) participated in the meropenem pharmacokinetic analysis. Operativ …
Noncompartmental and compartmental analyses of meropenem disposition in patients receiving 1-g intravenous intermittent infusions eve …
Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. Dandekar PK, et al. Pharmacotherapy. 2003 Aug;23(8):988-91. doi: 10.1592/phco.23.8.988.32878. Pharmacotherapy. 2003. PMID: 12921245 Clinical Trial.
STUDY OBJECTIVE: To assess the pharmacokinetics of meropenem administered as a 3-hour infusion. DESIGN: Randomized, crossover, open-label study. ...The 3-hour infusion optimized the pharmacodynamic profile of meropenem and worked within the constraints of sta …
STUDY OBJECTIVE: To assess the pharmacokinetics of meropenem administered as a 3-hour infusion. DESIGN: Randomized, crossover, …
Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies.
Germovsek E, Lutsar I, Kipper K, Karlsson MO, Planche T, Chazallon C, Meyer L, Trafojer UMT, Metsvaht T, Fournier I, Sharland M, Heath P, Standing JF; NeoMero Consortium. Germovsek E, et al. J Antimicrob Chemother. 2018 Jul 1;73(7):1908-1916. doi: 10.1093/jac/dky128. J Antimicrob Chemother. 2018. PMID: 29684147 Free PMC article. Clinical Trial.
BACKGROUND: Sepsis and bacterial meningitis are major causes of mortality and morbidity in neonates and infants. Meropenem, a broad-spectrum antibiotic, is not licensed for use in neonates and infants below 3 months of age and sufficient information on its plasma and CSF d …
BACKGROUND: Sepsis and bacterial meningitis are major causes of mortality and morbidity in neonates and infants. Meropenem, a broad-s …
Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy.
Langgartner J, Vasold A, Glück T, Reng M, Kees F. Langgartner J, et al. Intensive Care Med. 2008 Jun;34(6):1091-6. doi: 10.1007/s00134-008-1034-7. Epub 2008 Feb 23. Intensive Care Med. 2008. PMID: 18297267 Clinical Trial.
PATIENTS AND INTERVENTIONS: Six ICU patients were randomised to receive either meropenem 1 g IB every 12 h or a 0.5 g i.v. loading dose followed by 2 g i.v. CI over 24 h. After 2 days, regimens were crossed over. Meropenem pharmacokinetics were determined on …
PATIENTS AND INTERVENTIONS: Six ICU patients were randomised to receive either meropenem 1 g IB every 12 h or a 0.5 g i.v. loading do …
Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial.
Roggeveen LF, Guo T, Fleuren LM, Driessen R, Thoral P, van Hest RM, Mathot RAA, Swart EL, de Grooth HJ, van den Bogaard B, Girbes ARJ, Bosman RJ, Elbers PWG. Roggeveen LF, et al. Crit Care. 2022 Sep 5;26(1):265. doi: 10.1186/s13054-022-04098-7. Crit Care. 2022. PMID: 36064438 Free PMC article. Clinical Trial.
BACKGROUND: Adequate antibiotic dosing may improve outcomes in critically ill patients but is challenging due to altered and variable pharmacokinetics. To address this challenge, AutoKinetics was developed, a decision support system for bedside, real-time, data-driven and …
BACKGROUND: Adequate antibiotic dosing may improve outcomes in critically ill patients but is challenging due to altered and variable pha …
Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study.
Langan KM, Jacob J, Li J, Nation RL, Bellomo R, Howden B, Johnson PD. Langan KM, et al. Crit Care Resusc. 2014 Sep;16(3):190-6. Crit Care Resusc. 2014. PMID: 25161021 Clinical Trial.
OBJECTIVE: To test whether a prolonged 3-hour infusion of meropenem 500mg achieves an equivalent proportion of time above the minimal inhibitory concentration (MIC) (%TMIC) to that of meropenem 1000mg given over 30 minutes. ...Meropenem pharmacokinetics …
OBJECTIVE: To test whether a prolonged 3-hour infusion of meropenem 500mg achieves an equivalent proportion of time above the minimal …
Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion.
Mouton JW, Michel MF. Mouton JW, et al. J Antimicrob Chemother. 1991 Dec;28(6):911-8. doi: 10.1093/jac/28.6.911. J Antimicrob Chemother. 1991. PMID: 1816187 Clinical Trial.
The pharmacokinetics and penetration into suction blister fluid of meropenem was investigated after intermittent (10 mg/kg/6 h) and during continuous infusion (10 mg/kg/6 h) in eight healthy male volunteers in a crossover fashion. Concentrations in serum, urine and …
The pharmacokinetics and penetration into suction blister fluid of meropenem was investigated after intermittent (10 mg/kg/6 h …
52 results

Searches related to "meropenem pharmacokinetics"